Form 4: Amneal Pharmaceuticals Director Ted C. Nark Reports Stock Transactions
SEC Form 4 Filing
Director Ted C. Nark reports acquisition and disposal of Amneal Pharmaceuticals Class A Common Stock and Restricted Stock Units.
Summary
- On May 5, 2025, Director Ted C. Nark engaged in transactions involving Amneal Pharmaceuticals, Inc. (AMRX) Class A Common Stock and Restricted Stock Units.
- Nark acquired 40,258 shares of Class A Common Stock through the vesting of Restricted Stock Units.
- Following the reported transactions, Nark directly owns 341,029 shares of Class A Common Stock.
- Additionally, Nark was granted 34,819 Restricted Stock Units on May 6, 2025, which vest on the later of the day immediately preceding the issuer's first annual meeting of the stockholders following the date of grant and the day immediately following the first anniversary of the date of grant.
- These Restricted Stock Units represent a contingent right to receive one share of the Issuer's Class A Common Stock.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider trading activity.
Positives
- The acquisition of shares through vesting of restricted stock units can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's financial performance or future prospects.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into the trading activities of company insiders. This filing indicates the transactions of a director at Amneal Pharmaceuticals, offering insights into their investment decisions.
Stakeholder Impact
- Shareholders may be interested in the trading activity of company directors as it can provide insights into their confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 05/02/2024 | Reporting person was granted 40,258 restricted stock units vesting on May 5, 2025. |
| 05/05/2025 | Director Ted C. Nark acquired 40,258 shares of Class A Common Stock through vesting of Restricted Stock Units. |
| 05/05/2025 | Reporting person disposed of 40,258 restricted stock units. |
| 05/06/2025 | Nark was granted 34,819 Restricted Stock Units. |
| 05/08/2025 | Date of signature for the Form 4 filing. |
Keywords
Amneal Pharmaceuticals, AMRX, Form 4, Ted C. Nark, Director, Stock Transactions, Restricted Stock Units, Beneficial Ownership, Class A Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.